Zions Bancorporation National Association UT Acquires New Shares in Repligen Corporation (NASDAQ:RGEN)

Key Points

• Zions Bancorporation National Association UT has acquired 14,921 shares of Repligen Corporation valued at approximately $1.9 million, indicating growing institutional interest in the biotechnology sector.
• Repligen's recent earnings report showed a 14.8% year-over-year revenue increase to $182.37 million, although it missed the earnings per share consensus by $0.03.
• Analysts maintain a consensus rating of "Moderate Buy" for Repligen, with a price target averaging $169.45 amid recent adjustments by various financial institutions.

Zions Bancorporation National Association UT acquired a new stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 14,921 shares of the biotechnology company's stock, valued at approximately $1,899,000.

Other institutional investors have also recently bought and sold shares of the company. Raiffeisen Bank International AG acquired a new stake in Repligen during the fourth quarter valued at $29,000. Itau Unibanco Holding S.A. acquired a new stake in Repligen during the fourth quarter valued at $40,000. Signaturefd LLC boosted its position in Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 128 shares during the last quarter. Center for Financial Planning Inc. boosted its position in Repligen by 110.3% during the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 193 shares during the last quarter. Finally, UMB Bank n.a. boosted its position in Repligen by 99.4% during the first quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 332 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Price Performance

NASDAQ RGEN opened at $111.43 on Friday. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $182.52. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. The stock has a market capitalization of $6.26 billion, a PE ratio of -445.70, a P/E/G ratio of 2.05 and a beta of 1.05. The stock has a 50-day simple moving average of $122.76 and a 200 day simple moving average of $134.36.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.65% and a negative net margin of 2.05%. The business had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same period in the prior year, the firm posted $0.40 EPS. Repligen's revenue for the quarter was up 14.8% on a year-over-year basis. Research analysts anticipate that Repligen Corporation will post 1.72 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on RGEN shares. HC Wainwright reissued a "buy" rating and set a $180.00 price objective on shares of Repligen in a research report on Monday, May 5th. Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. JPMorgan Chase & Co. reduced their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Canaccord Genuity Group reduced their price target on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Finally, Evercore ISI reduced their price target on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Repligen presently has a consensus rating of "Moderate Buy" and a consensus price target of $169.45.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.